Tirzepatide is now cheaper than semaglutide at most major telehealth platforms — a reversal from 2024, when Mounjaro's brand-name premium kept it well above Ozempic and Wegovy on any honest price comparison. The shift traces directly to compounding pharmacy supply chains, aggressive platform competition, and the FDA's on-and-off shortage designations that determined which drugs compounders could legally produce and at what scale.
What actually changed between 2024 and 2026
The FDA removed semaglutide from its shortage list in early 2025, which legally restricted most 503B outsourcing facilities from compounding it at scale. Several large telehealth platforms — including some of the highest-volume GLP-1 prescribers — had to exit or dramatically curtail their compounded semaglutide programs. That supply compression pushed retail-equivalent prices for compounded semaglutide upward. Tirzepatide, by contrast, remained on the shortage list longer, and even after its removal, enforcement timelines gave compounders additional runway. The practical result: as of early 2026, publicly listed prices for compounded tirzepatide at major platforms typically run $199–$350 per month for starting doses, while compounded semaglutide — where still available — often lists at $250–$400 for equivalent weeks of supply, based on prices published directly on provider websites.
How platform fees distort the headline number
The drug cost alone is rarely the full story. Several platforms charge a separate monthly membership or provider fee — ranging from $20 to $99 per month depending on the service — that sits on top of the medication price. Others bundle prescriber visits, messaging access, and lab reviews into a single all-in price. When comparing platforms, a $199 tirzepatide listing with a $49 membership fee is more expensive than a $269 all-in tirzepatide program, but the former is the number most often surfaced in search results and ads. ClinicLayer's comparison tool standardizes for this by displaying total monthly cost, not medication price alone.
Brand-name prices haven't moved meaningfully
For patients using insurance or paying out of pocket for brand-name drugs, the calculus is different and less favorable. Eli Lilly's Zepbound (tirzepatide) carries a list price above $1,000 per month before rebates or coupons; Novo Nordisk's Wegovy (semaglutide 2.4mg) lists similarly. Lilly's direct-pay program through LillyDirect has offered vials of Zepbound at $349–$499 per month depending on dose — a meaningful discount, but still above most compounded alternatives. Novo has not offered a comparable direct-pay vial program for Wegovy as of this publication. Neither company has announced list price reductions for 2026, and both continue to compete primarily through payer rebates rather than sticker price cuts.
Why dose tier and titration schedule affect total cost
A monthly price quoted at a starting dose — typically 2.5mg for tirzepatide or 0.25mg for semaglutide — will not reflect what a patient pays after titrating to a therapeutic maintenance dose. Standard maintenance for tirzepatide is commonly 10mg–15mg weekly; for semaglutide, 1.7mg–2.4mg weekly. Most platforms charge more at higher doses, either through a tiered pricing structure or by requiring a larger volume of compounded medication. A patient who starts at $249 per month on tirzepatide may be paying $350–$450 at a 10mg maintenance dose six months later. Platforms that publish only their entry-level price without surfacing dose-adjusted costs make accurate comparison difficult without reading the fine print.
The regulatory variable no comparison can fully price in
Any compounded GLP-1 price should be understood as contingent on regulatory conditions that can change with limited notice. The FDA's enforcement posture toward compounders has shifted multiple times since 2023, and platform availability in specific states adds another layer of variability. Patients who have started a compounded GLP-1 program should understand that supply continuity is not guaranteed in the way it would be with a brand-name prescription filled at a retail pharmacy. On a pure dollars-per-month basis at current publicly listed prices, tirzepatide holds the price advantage for most patients in 2026 — but that advantage is structural only as long as the regulatory environment that enabled it holds.